CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Industry**: Oncology-focused biotechnology - **Location**: South San Francisco - **Key Personnel**: - Sean McCarthy (CEO) - Chris Ogden (CFO) - Rachel Lester (Chief Business Officer) - Wayne Chu (Chief Medical Officer) Core Points and Arguments Pipeline and Technology - CytomX has developed a unique Probody therapeutic platform aimed at masking antibodies to improve therapeutic windows in oncology [3][4] - The company is focused on two main clinical programs: - **Vasetatag masatikan (Vaseta M)**: An EpCAM-targeting Probody Topo-1 ADC for colorectal cancer [3][5] - **CX801**: A Probody version of interferon alpha-2b for melanoma [3][6] Financial Position - CytomX is well-funded, with cash reserves extending into Q2 2027, excluding potential milestones or new business developments [4] Vaseta M Program - The phase one study for Vaseta M is expanding to over 100 patients, with data updates expected by the end of Q1 2026 [8][19] - Initial data showed a 28% confirmed overall response rate and 94% disease control in late-line colorectal cancer patients [14][17] - The market for colorectal cancer is significant, with 1.9 million patients diagnosed annually, projected to exceed 3 million by 2040, and a $5 billion market opportunity in the U.S. for late-line treatment [10][22] Safety and Efficacy - Vaseta M demonstrated a favorable safety profile with no classic EpCAM toxicities, which have historically limited other EpCAM-targeting therapies [15][18] - The most common adverse event reported was grade 3 diarrhea, occurring in 21-22% of patients, which the company is actively investigating [19][36] Future Development Plans - CytomX aims to initiate a combination study of Vaseta M with bevacizumab to explore earlier lines of treatment [20][30] - The company plans to expand into other tumor types where EpCAM is expressed, potentially leading to a pan-tumor agnostic label [21][22] CX801 Program - CX801 is being developed as a novel immunotherapy for melanoma, particularly in patients who have progressed on checkpoint inhibitors [23][26] - The program aims to harness the activity of interferon alpha-2b while minimizing systemic toxicity through masking strategies [24][25] - Initial data from the combination with Keytruda is expected by the end of 2026 [30] Additional Important Content - CytomX has established partnerships with major pharmaceutical companies, including BMS, Amgen, and Moderna, enhancing its business development capabilities [4] - The company emphasizes the importance of understanding the etiology of adverse events, particularly gastrointestinal toxicities, to optimize patient management [37][38] - The strategic decision to focus on colorectal cancer was based on the abundance of the EpCAM target and the unmet medical need in this area [40][41] Conclusion CytomX Therapeutics is positioned at the forefront of innovation in oncology with its differentiated pipeline and strategic focus on unmet needs in colorectal cancer and melanoma. The upcoming data releases and ongoing studies are critical for validating the efficacy and safety of its lead programs, which could significantly impact the treatment landscape in these areas.

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Event**: FY Conference held on December 04, 2025 - **Key Technology**: Probody technology, which masks therapeutic proteins to enhance targeting in tumor tissues while reducing effects on healthy tissues [1][3][4] Core Points and Arguments Probody Technology - Probody technology allows for selective binding of therapeutic proteins in tumor tissues by masking them, which is cleaved by tumor-associated proteases [3][4] - This innovative approach has been validated through encouraging phase one data on CX-2051 for colorectal cancer [1][2] CX-2051 Development - CX-2051 targets EpCAM, a tumor antigen abundant in colorectal cancer, but previously faced challenges due to toxicity in normal tissues [6][7] - The phase one study showed a confirmed response rate of 28% in a late-stage metastatic colorectal cancer patient population, with a median of four prior therapies [10][11] - The drug demonstrated a progression-free survival of 5.8 months and a 94% disease control rate, indicating significant efficacy in a difficult-to-treat population [11] Future Development Plans for CX-2051 - The company plans to expand the study to include about 100 patients and aims to provide updates on efficacy and safety in Q1 of the following year [12][13] - The immediate goal is to get CX-2051 on a path to registration as a monotherapy, with potential studies against standard care in later lines of therapy [15][17] - There is a vision for CX-2051 to potentially replace irinotecan in earlier lines of colorectal cancer therapy [16][17] CX-801 Development - CX-801, a masked interferon alpha-2b, is being developed for melanoma, leveraging the same masking strategy to improve tolerability while activating the immune response [21][22] - Early data showed activation of interferon-responsive genes and recruitment of T cells in the tumor microenvironment, setting the stage for combination therapy with Keytruda [24][25] Other Programs and Partnerships - CytomX is also exploring CX-908, a dual masked T cell engager targeting P-cadherin and CD3, with promising preclinical results [26][27] - The company is open to partnerships for further development, especially in the T cell engager space, while maintaining a focus on productization [28][29] Financial Position - As of the end of Q3 2025, CytomX had $144 million in cash, which has since increased to approximately $158 million, providing funding into Q2 2027 [33] - This financial position supports ongoing clinical studies and the expansion of their therapeutic pipeline [33] Additional Insights - The company has experienced a transformational year in 2025, with significant advancements in their clinical programs and technology validation [5][33] - There is a strong emphasis on maintaining urgency and speed in development, with potential for broadening the application of their Probody platform across various solid tumors [18][30]